The PTEN/NRF2 axis promotes human carcinogenesis

Antioxidants and Redox Signaling

Volumn 21, Issue 18, 2014, Pages 2498-2514

  Rojo, Ana I ^a,b   Rada, Patricia ^a,b   Mendiola, Marta ^c   Ortega Molina, Ana ^d   Wojdyla, Katarzyna ^e   Rogowska Wrzesinska, Adelina ^e   Hardisson, David ^a,c   Serrano, Manuel ^d   Cuadrado, Antonio ^a,b  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; ENDOMETRIOID CARCINOMA; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER CELL LINE; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; ANIMAL; GENETICS; LIVER; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HEME OXYGENASE-1; HUMANS; LIVER; MICE; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84907929068     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5843     Document Type: Article

References (60)

1. Almazari I, Park JM, Park SA, Suh JY, Na HK, Cha YN, Surh YJ. Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target. Carcinogenesis 33: 368-376, 2012.
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525, 2012.
3. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, Xue P, Pi J, Kleeberger SR, and Bell DA. Identification of novel NRF2-regulated genes by ChIPSeq: Influence on retinoid X receptor alpha. Nucleic Acids Res 40: 7416-7429, 2012.
4. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
5. Dinkova-Kostova AT, and Wang XJ. Induction of the Keap1/Nrf2/ARE pathway by oxidizable diphenols. Chem Biol Interact 192: 101-106, 2011.
6. Gebremedhin D, Terashvili M, Wickramasekera N, Zhang DX, Rau N, Miura H, and Harder DR. Redox signaling via oxidative inactivation of PTEN modulates pressure-dependent myogenic tone in rat middle cerebral arteries. PLoS One 8: E68498, 2013.
7. Gobom J, Nordhoff E, Mirgorodskaya E, Ekman R, and Roepstorff P. Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrixassisted laser desorption/ionization mass spectrometry. J Mass Spectrom 34: 105-116, 1999.
8. Greiner R, Palinkas Z, Basell K, Becher D, Antelmann H, Nagy P, and Dick TP. Polysulfides link H2S to protein thiol oxidation. Antioxid Redox Signal 19: 1749-1765, 2013.
9. Hayes JD and Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39: 199-218, 2014.
10. Heneberg P. Reactive nitrogen species and hydrogen sulfide as regulators of protein tyrosine phosphatase activity. Antioxid Redox Signal 20: 2191-2209, 2014.
11. Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Ceballos ML, and Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181: 680-689, 2008.
12. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
13. Jaramillo MC and Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27: 2179-2191, 2013.
14. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, and Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486-5496, 2010.
15. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, and Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446-451, 2010.
16. Kitagishi Y and Matsuda S. Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med 31: 511-515, 2013.
17. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, and Rhee SG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101: 16419-16424, 2004.
18. Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, and Jorgensen TJ. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics 4: 873-886, 2005.
19. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
20. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342, 2002.
21. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, and Cuadrado A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279: 8919-8929, 2004.
22. McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Dimerization of substrate adaptors can facilitate cullinmediated ubiquitylation of proteins by a " tethering mechanism: A two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 281: 24756-24768, 2006.
23. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22: 66-79, 2012.
24. Muscarella LA, Parrella P, D'lessandro V, la Torre A, Barbano R, Fontana A, Tancredi A, Guarnieri V, Balsamo T, Coco M, Copetti M, Pellegrini F, De Bonis P, Bisceglia M, Scaramuzzi G, Maiello E, Valori VM, Merla G, Vendemiale G, and Fazio VM. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 6: 710-719, 2011.
25. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, and Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930, 2000.
26. Na HK and Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 67: 353-365, 2014.
27. Nair S, Barve A, Khor TO, Shen GX, Lin W, Chan JY, Cai L, and Kong AN. Regulation of Nrf2-And AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 31: 1223-1240, 2010.
28. Numajiri N, Takasawa K, Nishiya T, Tanaka H, Ohno K, Hayakawa W, Asada M, Matsuda H, Azumi K, Kamata H, Nakamura T, Hara H, Minami M, Lipton SA, and Uehara T. On-off system for PI3-kinase-Akt signaling through Snitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci U S A 108: 10349-10354, 2011.
29. Odriozola L, Singh G, Hoang T, and Chan AM. Regulation of PTEN activity by its carboxyl-Terminal autoinhibitory domain. J Biol Chem 282: 23306-23315, 2007.
30. Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, Munoz-Martin M, Gomez-Lopez G, Canamero M, Mulero F, Pastor J, Martinez S, Romanos E, Mar Gonzalez-Barroso M, Rial E, Valverde AM, Bischoff JR, and Serrano M. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab 15: 382-394, 2012.
31. Palmero I and Serrano M. Induction of senescence by oncogenic Ras. Methods Enzymol 333: 247-256, 2001.
32. Pitha-Rowe I, Liby K, Royce D, and Sporn M. Synthetic triterpenoids attenuate cytotoxic retinal injury: Cross-Talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest Ophthalmol Vis Sci 50: 5339-5347, 2009.
33. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, and Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31: 1121-1133, 2011.
34. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobon-Velasco JC, Devijver H, Garcia-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, and Cuadrado A. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/ beta-TrCP axis. Mol Cell Biol 32: 3486-3499, 2012.
35. Risinger JI, Hayes AK, Berchuck A, and Barrett JC. PTEN/ MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736-4738, 1997.
36. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, and Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 588-598, 2010.
37. Rojo AI, Medina-Campos ON, Rada P, Zuniga-Toala A, Lopez-Gazcon A, Espada S, Pedraza-Chaverri J, and Cuadrado A. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic Biol Med 52: 473-487, 2012.
38. Rojo AI, Rada P, Egea J, Rosa AO, Lopez MG, and Cuadrado A. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci 39: 125-132, 2008.
39. Rojo AI, Sagarra MR, and Cuadrado A. GSK-3beta downregulates the transcription factor Nrf2 after oxidant damage: Relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105: 192-202, 2008.
40. Rojo AI, Salinas M, Martin D, Perona R, and Cuadrado A. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci 24: 7324-7334, 2004.
41. Sakamoto K, Iwasaki K, Sugiyama H, and Tsuji Y. Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell 20: 1606-1617, 2009.
42. Salazar M, Rojo AI, Velasco D, de Sagarra RM, and Cuadrado A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 281: 14841-14851, 2006.
43. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, and Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45: 860-867, 2013.
44. Satoh H, Moriguchi T, Takai J, Ebina M, and Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73: 4158-4168, 2013.
45. Shevchenko A, Wilm M, Vorm O, and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858, 1996.
46. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, and Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 105: 13568-13573, 2008.
47. Simpson L and Parsons R. PTEN: Life as a tumor suppressor. Exp Cell Res 264: 29-41, 2001.
48. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: E420, 2006.
49. Singh G and Chan AM. Post-Translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets 11: 536-547, 2011.
50. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, and Wistuba, II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16: 3743-3753, 2010.
51. Sporn MB and Liby KT. NRF2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.
52. Sprenger RR and Horrevoets AJ. Proteomic study of caveolae and rafts isolated from human endothelial cells. Methods Mol Biol 357: 199-213, 2007.
53. Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, and Giamas G. The regulatory roles of phosphatases in cancer. Oncogene 33: 939-953, 2014.
54. Suzuki T, Motohashi H, and Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34: 340-346, 2013.
55. Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, Motohashi H, and Yamamoto M. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol 34: 900-913, 2014.
56. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, and Ellenson LH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940, 1997.
57. Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Barton GJ, and Leslie NR. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumorsuppressing phenotype, but not with AKT activity. Sci Signal 5: Ra18, 2012.
58. Wang XJ, Hayes JD, Higgins LG, Wolf CR, and Dinkova-Kostova AT. Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para-And orthohydroquinones. Chem Biol 17: 75-85, 2010.
59. Xu C, Yuan X, Pan Z, Shen G, Kim JH, Yu S, Khor TO, Li W, Ma J, and Kong AN. Mechanism of action of isothiocyanates: The induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther 5: 1918-1926, 2006.
60. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, and Biswal S. Loss of Kelch-like ECH-Associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9: 336-346, 2010.